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Abstract: A “transitional care pharmacist” (TCP) was deployed within an acute care setting to 
identify opportunities for improved continuity of care. The provision of medication reconcili-
ation services, drug consultation, patient counseling and planning for after-hospital care was 
time consuming but also fruitful, resulting in roughly nine interventions per patient. Areas with 
the greatest potential for morbidity reduction were the resumption of home medications during 
the acute stay and at discharge. Allergy identiﬁ  cation was a key contribution at admission, as 
was the provision of a detailed follow-up plan at discharge. Targeting high-risk patients and 
spreading portions of the work to other disciplines could achieve added efﬁ  ciency in this service. 
Results have value to hospitals implementing medication reconciliation programs.
Keywords: patient safety, medication reconciliation, transitional care, pharmacist 
Patient transitions across settings of care are a major cause of medication errors and 
adverse drug events (ADEs) (Forster et al 2003; Boockvar et al 2004). An important 
component of these transitions is the accurate and complete transfer of a patient’s 
medication information (Sexton et al 2000). In 2005, the Joint Commission on the 
Accreditation of Health Care Organizations (JCAHO) made “medication reconcilia-
tion” a national patient safety goal (JCAHO 2005). However, no direction in accom-
plishing this goal is widely available (Barnsteiner 2005) and limitations exist for many 
of the current localized attempts at safe practice (Gleason et al 2004).
One potential approach to improving medication safety during transitions in care 
is the development of integrated information systems. However, earlier work suggests 
that there are vulnerabilities in the care process despite attempts to smooth transi-
tions using electronic medical record systems (Bayley et al 2003b). To address these 
vulnerabilities requires more than a conduit for the transmission of an improved care 
plan; it requires the use of a “linking agent” to bridge the gap across settings (Bayley 
and Savitz 2004).
A number of studies have explored the use of pharmacists at various points in the 
acute care stay. For example, admission medication histories taken by pharmacists 
have proved more accurate and complete than those taken by nurses (Gleason et al 
2004), and pharmacy technicians are effective in the role of reconciling medication 
information (Michels and Meisel 2003). Pharmacists participating in medical rounds 
reduce medication errors in the ordering stage as well as acute care costs (Leape et al 
1995, 1999; Boyko, Jr. et al 1997; McMullin et al 1999; Scarsi et al 2002; Kucukarslan 
et al 2003). Pharmacists provide effective discharge education (Cameron 1994) and 
can reduce later emergency department visits by making follow-up phone calls to 
patients post-discharge (Dudas et al 2001). Therapeutics and Clinical Risk Management 2007:3(4) 696
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One area not studied is the role and impact of a pharmacist 
focused on transitional care issues. Transitional care is a set 
of actions designed to ensure the coordination and continuity 
of health care as patients transfer between different locations 
and different levels of care (Coleman and Berenson 2004). 
A “transitional care pharmacist” (TCP) would therefore do 
much more than gather a patient’s current and past medical 
history. The TCP would evaluate the appropriateness and 
effectiveness of each medication, uncover adherence issues 
and potential medication injuries, and provide plans for 
appropriate monitoring by following providers. Pharmacists, 
through the nature of their training, are uniquely positioned to 
customize drug regimens based on each patient’s individual 
situation and to impact medication-related problems that 
occur during care transitions. 
The present study describes the role of a TCP. We also 
describe the speciﬁ  c improvement opportunities available 
throughout a hospital stay and upon discharge. 
Methods
Setting and subjects
The study was carried out at a 483-bed, tertiary care com-
munity hospital in Portland, Oregon. The study hospital is 
part of a fully-integrated delivery system that also includes 
health plans, medical group, and home and community ser-
vices. Eligible participants in the study were HMO Medicare 
patients whose primary care physician was employed by the 
hospital system and who had an in-patient stay of at least one 
day during the period Feb 10, to October 31, 2004. Overnight 
“observation” patients, patients with documented memory or 
mental health issues that might prevent informed consent, and 
patients on hospice were excluded. Potential study subjects 
were identiﬁ  ed from the hospitalist admitting census list, and 
were assigned for evaluation and follow-up by a TCP. The 
local Institutional Review Board approved the study.
Clinical pharmacist role
The TCP was doctoral prepared with residency training 
in internal medicine. Their role was developed from two 
pilot projects and an FMEA (Failure Mode and Effects 
Analysis) on medication information transfer across 
care settings. Pharmacy residents in the study hospital 
conducted both pilot projects. In the first pilot, a clinical 
pharmacist rounded with hospitalists to consult on medica-
tions, and was found to be quite helpful to them. In the second, 
a pharmacist focused on patient discharge education, 
much to the appreciation of inpatient nurses. The FMEA 
was conducted as part of a study on health information 
technology and medication information transfer (Bayley 
et al 2003a). Based on both the value perceived from 
the pilot projects and the risks identified in the FMEA, 
the TCP role was focused on six major activities: 1) rec-
onciling all information sources to produce an accurate 
list of patients’ medications on admission; 2) providing 
drug selection, dosing, and other recommendations to 
the hospitalists during the hospital stay (see below); 
3) developing a comprehensive discharge medication list; 
4) conducting patient discharge education; 5) transmit-
ting the discharge medications information, including 
follow-up monitoring plan to the primary care provider; and 
6) contacting the patient by telephone within 3–5 days of 
discharge to confirm their understanding of their medica-
tions and answer any questions. Prior to the onset of the 
study, the pharmacist rounded with each hospitalist for 
two successive days and became formally integrated into 
the hospitalist team.
Classiﬁ  cation of interventions
Interventions made by the pharmacist were classiﬁ  ed using 
a scheme adapted from Hatoum et al (1988), similar to the 
classiﬁ  cation used by the ADE Prevention Study Group 
(Leape et al 1991; Bates et al 1995). The classiﬁ  cation 
categories are reproduced in Table 1 with examples of each. 
Each category is mutually exclusive to ensure consistent 
coding of similar interventions. 
In addition to these categories, each intervention was 
rated as having a short-term or long-term impact, and an 
importance ranging from simple cost savings to prevention 
of mortality. Short-term impacts were classiﬁ  ed as those 
having to do with the pharmacotherapeutics and/or injury 
avoidance during the current admission; long-term impacts 
were classiﬁ  ed as those interventions affecting chronic dis-
ease care and/or prevention practice (eg, pneumonia vaccine). 
The importance ratings were intentionally made into four 
broad categories to simplify the classiﬁ  cation task and reﬂ  ect 
the predictive rather than actually observed degree of harm. 
Classiﬁ  cation into the “prevented serious morbidity” versus 
“prevented potential ADE” was based on the pharmacist’s 
judgment as to both the severity of potential harm to the 
patient and the probability that a speciﬁ  c medication would 
result in harm for a speciﬁ  c patient, given their current health 
condition.
The clinical pharmacist performed all of these ratings. To 
verify the reasonableness of the ratings, ratings for the ﬁ  rst 20 
patients in the study were independently reviewed by the phar-
macy manager and study author (SS). Few differences were Therapeutics and Clinical Risk Management 2007:3(4) 697
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Table 1 Classiﬁ  cation, deﬁ  nition and example of pharmacist interventions
Intervention topic  Deﬁ  nition  Example
Add/change/delete medication
Duplicate therapy  Discontinue one of two or more  Patient taking both niacin and lovastatin.
  medications that have similar effects  Discontinue niacin – patient with good lipid control.
Guideline adherence   Recommend lab tests consistent with  Check lipid panel for patient with history
  current international guidelines  of acute myocardial infarction.
Indication without a medication  Patient has a diagnosis for which a  Heart failure patient needs beta-blocker therapy.
  medication is known to be appropriate 
Medication selection  Change medication to one with fewer  Change glyburide to glipizide for patient with
  side effects, greater chance of patient  renal insufﬁ  ciency who has experienced early
  compliance, or substitute for two other  morning hypoglycemic events.
 medications.   
Medication without indication  Discontinue a medication because a   Discontinue oral pantoprazole in patient
  patient no longer has symptoms, or lab  no longer at risk for gastric stress ulcers.
  values obviate the need 
Notable adverse drug reaction  Recommend discontinuing or changing  Discontinue bedtime temazepam & as-needed
  a medication due to a moderate-severe  lorazepam for patient who is over-sedated.
 reaction 
Potential drug/food/disease  Discontinue drug which has propensity  Discontinue diazepam in 93 year-old female
interaction  to worsen a patient co-morbidity, eg,   who has recently experienced falls and a head
  likelihood of fall  contusion. Use trazodone for sleep.
Allergies
Allergy information updated/deleted  Change allergy record to reﬂ  ect current  Remove meclizine allergy – patient takes at
  status of allergies, including updates from  home without problem.
 patient 
Existing allergy reaction  Identify the exact type of reaction to a  Sulfa causes hives and shortness of breath.
 known  allergy 
New allergy identiﬁ  ed  Patient exhibits an allergy that has not  Penicillin causes rash.
  been documented elsewhere 
Patient allergic to original medication  Change an ordered medication when  Patient allergic (rash) to ciproﬂ  oxacin that
ordered  documentation shows an existing patient  was ordered for enterbacter cloacae in the urine. 
  allergy.  Change to ceftriaxone.
Cost
Nonformulary/insurance issue  Change a medication to the formulary  Change pantoprazole back to over-the-counter
  agent covered by a patient’s insurance.  omeprazole at discharge.
Patient cannot afford original  Change to a less expensive medication  Change pantoprazole to over-the-counter
medication   omeprazole. 
Dosing
Appropriate dosing  Change medication dose based on patient  Change ophthalmic drops, Xalatan, from both
  age, comorbidities, or other medications  eyes to right eye only.
Dose adjustment for drug  Increase or decrease medication dose in  Decrease weekly warfarin dose in response
interaction  consideration of other medications  to added amiodarone therapy.
Renal/hepatic dosing  Change medication dose based on renal  Decrease dose of allopurinol to 150 mg/d
  function  (from 300 mg/d) for estimated creatine 
    clearance of 20 ml/min.
Sub-therapeutic dosing  Increase medication dose in order to  Atenolol dose reduced from 100 mg/d
 achieve  beneﬁ  t, or resume previous  to 50 mg/d upon admit. Now BP to 171/99.
  levels at discharge to what the patient  Recommend resume home dose of 100 mg.
  had prior to admission. 
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noted. These were discussed with the pharmacist, changed, 
and henceforth became the standard rating practice. 
A database was developed to document all interventions. 
Data collected included patient identiﬁ  ers, date, type of 
recommendation (dosing, medication change, etc), the timing 
of the recommendation (admission, discharge, follow-up), 
the expected time-frame of impact (short-term or long-term), 
the estimated signiﬁ  cance of the intervention, and whether the 
recommendation was accepted by the hospitalist.
Time spent on TCP interventions was assessed mid-point in 
the study period using two methods. First, the TCP was queried 
to estimate the time spent on each of the above activities in a 
typical day. She reviewed her work over a 1-week time period 
and approximated the amount of time on each activity, provid-
ing a range, eg, 30 to 45 minutes. Second, a trained observer 
shadowed the TCP for a day to understand these estimates 
and identify any time commitments the TCP had overlooked. 
Time estimates were revised at study close, to take into account 
feedback from these observations and also the increased 
efﬁ  ciency with the maturation of the TCP program.
Results
During the course of the study, 105 patients were eli-
gible for treatment by the transitional care pharmacist. 
Ninety-nine (99) of these patients were seen by the TCP, 
and 91 had at least one intervention. Six patients were 
deemed eligible but were discharged too quickly for the 
TCP to play a role. Eight patients did not need pharmacy 
intervention. Demographics of the study population are 
provided in Table 2.
In total there were 927 interventions performed, an aver-
age of 9.4 per patient seen. The attending physician accepted 
approximately 96 percent of the TCP recommendations, and 
recommended changes were implemented by that physician 
or by the pharmacist.
The TCP role with these patients is best characterized 
by describing ongoing daily tasks and time spent with each 
patient (Table 3). Roughly one-quarter (26%) of TCP time 
was spent at admission on the dual tasks of gathering histori-
cal medication information and conducting a comprehensive 
patient medication history. At times, this included phone calls 
to community pharmacists or family members for additional 
information, as well as research to verify the appropriate-
ness of current medications. These tasks consumed roughly 
83 minutes per patient, on average. Another 22% of time 
(75 minutes) was spent rounding on patients, reviewing lab 
work, and consulting with hospitalists on the medication 
regimens. Thirty-eight percent of time (roughly two hours 
per patient) was spent at discharge, in preparation of the 
Table 2 Description of study population
Descriptor  Percentage or  
 value
Average age  78.9
Age range  60 to 94
Age > 85  31%
Male 33%
Avg. number of medications
Currently taking  9.8
3+ prior inpatient admissions in 
prior year  38%
Cardiac DRG  11%
Neuromusculoskeletal DRG  19%
Medical-GI DRG  20%
Medical-respiratory DRG  19%
Discharge to SNF or foster care  33%
Table 1 (continued)
Intervention Topic  Deﬁ  nition  Example
Supra-therapeutic dosing  Decrease medication dose in patient  Decrease dose of glyburide 3 mg bid to daily
  when warranted by lab results or patient  for blood glucose of 38 this am.
 side-effects 
Other
Patient counseling  Explain to patient or family the  Counsel patient on inhaler technique and
  importance of a medication, reasons  provided a visual aid for appropriate inhaler
  for changes, or how to take a medication   technique steps at discharge.
Route change  Any change in the medication’s route of  Change IV to oral ciproﬂ  oxacin – patient
  administration based on the patient’s  able to take oral medications.
 clinical  status 
Vaccines missing  Order a guideline-indicated vaccine and  Pneumovax.
  there is no recent documentation 
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discharge medication list, patient counseling, and detailed 
follow-up plans of care sent to primary care providers. 
The remaining time was required for properly 
identifying patients for intervention and documenting all 
interventions, tasks required by the study. Daily print-
outs of hospitalist patients needed to be screened for the 
HMO Medicare patients and to eliminate patients already 
approached for participation. In addition, the patient 
chart was reviewed to note any mention of dementia or 
cognitive issues that would make study informed consent 
impossible.
The TCP could not provide accurate estimates of the 
total time spent on patient follow-up calls. While each call 
was brief (3–5 minutes), the calls were interspersed with 
other activities and often involved multiple calling attempts 
to reach the patient.
Nature of recommendations
Roughly equal numbers of recommendations were given 
at admission, during the hospitalization, and at discharge 
(Table 4). 
The type of recommendations varied over the course of 
the stay. At admission, over two-thirds (196/285, 69%) of 
the interventions dealt with allergies: clarifying, adding, or 
deleting allergy information. Recommendations involving 
medication additions or deletions tended to occur either at a 
later point within the stay or at discharge (Table 4). 
Pharmacist interventions involved long-term beneﬁ  t as 
well as short-term impact. In fact, almost as many recom-
mendations addressed ongoing chronic disease issues as the 
more short-term issues such as symptom relief (Table 5). 
The most frequent type of recommendations were those 
deemed to have both short- and long-term impacts, such as 
acid-reducing strategies for gastroesophageal reﬂ  ux disease 
or medications for seasonal allergies. 
The pharmacist rated close to 30% of her recommen-
dations to have prevented serious morbidity (Table 6). 
Not surprisingly, the speciﬁ  c recommendations thought 
to achieve the greatest morbidity avoidance were those 
involving the addition of a medication. Thirty-one percent 
of all morbidity-reducing recommendations involved add-
ing a medication as warranted by the patient’s indications 
(Table 7).
The addition of a medication occurred most frequently 
during the hospital stay, and included four types of recom-
mendations. First, the pharmacist recommended resuming 
home chronic disease medications where these had been 
held at admission (44% of the recommendations). These 
medications included antidepressants as well as statins, 
insulin, and antihypertensives. Next most frequently (37% of 
recommendations) the pharmacist recommended new chronic 
disease medications that had potential long-term value and 
were not contraindicated in the hospital setting. A third set 
of recommendations (11%) was for symptom relief, such 
as for constipation due to narcotic use or saline nasal spray 
for irritation due to oxygen tubes. Finally, the pharmacist 
recommended substitution of one medication for another, 
to enhance cost-effectiveness.
A small (n = 27) but potentially important set of 
pharmacist interventions in the hospital setting involved 
deleting medications that were no longer indicated for the 
patient. Over one-half of these (52%) involved situations 
Table 3 Time estimates for transitional care pharmacist tasks
TCP Task  Estimated time 
 required  (minutes)
 Range  Avg  Percent
Admission    
Collect historical data  30–60  45  13%
print/read H&Ps     
print/reconcile EHR     
draft care plan     
review/document pertinent labs     
Medication history by patient  30–45  37.5  11%
interview 
patient interview     
review paper chart data     
In-hospital    
Daily Rounding  60–90  75  22%
update new labs/culture 
information    
assess current progress     
ascertain discharge plan     
follow-up on interventions made     
Discharge    
Type discharge medication list   15–30  22.5  7%
Counsel patient   20–40  30  9%
Write follow-up care plan  60–90  75  22%
write care plan     
update EHR ﬂ  owsheet     
update EHR medication list     
update EHR allergies     
route ﬁ  nal document to PCP     
Other    
Identify patients from daily  30–45  37.5  11%
printouts 
Enter data on all   10–15  12.5  4%   
recommendations made 
    
Total time per patient (min)  255–415  335  100%
Total time per patient (hr)  4.3–6.9  5.6 
    
Patients per 40 hour week  9.4–5.8  7.2 Therapeutics and Clinical Risk Management 2007:3(4) 700
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Table 4   Timing of interventions
  Phase of care
Intervention Admission  In-hospital  Discharge  Follow-up  Total
Add/change/delete medication       
Duplicate therapy  4  19  9  2  34
Guideline adherence   4  23  1  0  28
Indication without a medication  33  103  147  9  292
Medication  selection  3 23 11 2  39
Medication without indication  6  27  11  0  44
Notable adverse drug reaction  3  9  0  0  12
Potential drug/food/disease interaction  9  17  11  1  38
Allergy       
Allergy Information updated/deleted  27  1  0  0  28
Existing allergy reaction  120  4  0  0  124
New allergy identiﬁ   ed  49  4 1 1  55
Patient allergic to ordered medication   0  1  0  0  1
Cost       
Nonformulary/insurance  issue  0  0 6 0  6
Patient can’t afford original medication  0  6  10  0  16
Dosing       
Appropriate  dosing  5 20 31 3  59
Dose adjustment for drug interaction  1  1  1  0  3
Renal/hepatic dosing  0  17  3  1  21
Sub-therapeutic dosing  5  20  9  0  34
Supra-therapeutic dosing  1  11  2  1  15
Other       
Patient counseling  6  23  9  3  41
Route change  0  15  1  0  16
Vaccines missing  9  10  2  0  21
Total  285  354 265 23  927
Percentage by phase of care  31%  38% 29% 2%  100%
where either lab data or improved patient symptoms war-
ranted discontinuation and one-third (33%) involved medi-
cations that simply appeared inappropriate or unnecessary 
(eg, estrogen replacement therapy in an 83-year old). A 
small number of medications (n = 4) were discontinued upon 
ﬁ  nding that the patient had not been taking the medication 
at home as previously thought and it was no longer deemed 
clinically necessary to continue therapy.
The discharge role of the pharmacist was focused on 
returning the patient to a longer-term medication regimen, 
with the resumption of medications previously held during 
the hospital stay. Over half (147 of 265) of the recommenda-
tions at this stage were to add a medication, and 85% of these 
(125) involved resumption of a previous home medication. 
Also seen at discharge were a few more recommendations 
(10 of 265, 4% of all discharge recommendations) involving 
insurance or cost issues for the patient.
Discussion 
A clinical pharmacist focusing on medication reconcilia-
tion issues in a community hospital setting will ﬁ  nd many 
opportunities for improvement, effectively combining transi-
tional care with more traditional clinical pharmacy consulta-
tion (Jacobson 2002). However, doing this work in thorough 
fashion takes a great deal of time – between three to four 
hours per patient. It should be noted that the interventions 
of this pharmacist went far beyond simple reconciliation of 
medication names and doses on lists, but included extensive 
research on current medications, advising the hospitalist 
physicians, development of customized pharmaceutical care 
plans, patient education, and communication of the post-
discharge treatment and monitoring plan to the ambulatory 
care provider. Each of these transitional care activities can 
be time-consuming in an elderly population with complex 
medication regimes.
If the TCP approach were considered for more wide-
spread adoption, it would require greater efﬁ  ciency and 
targeting. Based on our work, we would recommend that 
the most appropriate patients for this service are those 
who take multiple medications, take high-risk medica-
tions, who are inexperienced with their medication re-
gime, or whose reason for hospitalization was medication Therapeutics and Clinical Risk Management 2007:3(4) 701
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related. Many times these patients are those with multiple 
chronic conditions. This would imply differing levels of 
medication reconciliation with the greatest resources 
devoted to the patients at greatest risk. A more general 
approach to the greater population might target those areas 
that were most frequently identiﬁ  ed as problematic.
Efﬁ  ciency in the service could be achieved by making it 
a team effort rather than dependent on a single pharmacist. 
While much of the work done in this study would require 
pharmacy expertise – to recommend resumption of medica-
tions, delete medications, change doses, or identify critical 
lab work that needed to be done – a different discipline (eg, 
nursing) could handle a portion of the allergy clariﬁ  cation, 
conduct the patient counseling, and ensure preventive care 
like pneumonia vaccination. 
There are advantages to having pharmacists conduct 
medication histories, since they can use their expertise to 
check for adherence issues, clarify doses based on knowl-
edge of available medication strengths, differentiate true 
drug allergies from other intolerance issues, and provide an 
evidence resource to the clinical team. The pharmacist in the 
present study was also able to identify medications and doses 
using the patient’s lay knowledge (eg, “my water pill”) and a 
description of the actual tablet. At the same time, the expense 
of a clinical pharmacist would warrant that these tasks be 
done for the most high-risk patients, and also that this work 
substitute for the time of nurses and physicians. 
The greatest area for morbidity reduction appears to be 
the resumption of beneﬁ  cial medications that have been held 
at admission (31% of all morbidity-reducing interventions). 
In the present study, the pharmacist tended to add back home 
medications during the hospital stay (ie, after the 2nd or 3rd 
hospital day), addressing a potentially important problem 
for longer acute stays. The Institute for Safe Medication 
Practices has issued an “alert” on this issue (ISMP 2005). 
Many types of medications cannot be held for more than a few 
days without impacting patient health. Unless the patient’s 
medication administration record is compared each day with 
the previous home medications, these medications will be 
missed. In addition, there are medications (eg, beta-blockers, 
clonidine, benzodiazepines) that should be tapered, not 
completely held at admission. 
The analysis offers conﬁ  rmation that good discharge 
orders are dependent upon thorough admission data 
collection. The principal task at discharge was to resume 
home medications that may have been left off discharge 
orders (approximately 85% of the recommendations to add 
medications at discharge). Only 10% of added medications 
were new medications and a small fraction (5%) involved 
additions for symptom relief or the substitution of a new 
medication for something else. We would suspect that the 
number of medications resumed at discharge in this study 
might be less than usual, given that many medications were 
already re-started within the stay.
One unexpected study ﬁ  nding was the high frequency 
of allergy-related recommendations at admission. Over 
two-thirds (69%) of interventions at admission dealt with 
allergies – clarifying, adding or deleting allergy information. 
Table 5 Expected temporal impact of interventions
Expected temporal impact  Number  Percentage
Short-term 190  20.5%
Long-term 151  16.3%
Both short-term and long-term  583  62.9%
Not rated (inadvertently)  3  0.3%
Total 927  100%
Table 6 Importance of interventions as rated by pharmacist
Rating Importance    Number  Percentage  Examples
1  Prevented Mortality  0  0.0%  Avoided administration of a medication listed as 
        an allergy with an anaphylactic reaction in medical record.
2  Prevented Serious   273  29.2%  Held a medication in response to supratherapeu-
  Morbidity      tic drug levels, ie, digoxin, theophylline, warfarin, etc. 
3 Prevented  Potential  626  67.7%  Lowered warfarin dose empirically in response 
  ADE or Standard of      to addition of amiodarone.Added ACEI therapy
  Practice      to patient with both diabetes and hypertension.
4  Cost or Product  27  2.9%  Switch PPI therapy from esomeprazole to 
  Selection      pantoprazole per approved therapeutic interchange.
        Adherence to an established outpatient medication 
       formulary.
  Not Rated  1  0.1%  (Inadvertently not rated)
Total   927  100.0% Therapeutics and Clinical Risk Management 2007:3(4) 702
Bayley et al
Table 7 Interventions with an impact on decreasing morbidity
Intervention   Number of recommendations  % of all morbidity reducing
  estimated to decrease morbidity  recommendations
Indication w/o a medication  85  31%
Existing allergy, reaction  22  8%
Vaccines missing  21  8%
Med w/o indication  15  5%
Potential drug/food/disease interaction  15  5%
 Patient counseling   15  5%
Medication selection  15  5%
Appropriate dosing  13  5%
Duplicate therapy  13  5%
Subtherapeutic dosing  11  4%
Supratherapeutic dosing  10  4%
Renal/hepatic dosing  10  4%
Guideline only   9  3%
Notable adverse drug reaction  8  3%
New alergy identiﬁ  ed  4  1%
Dose adjustment for drug interaction  2  1%
Route change  2  1%
Allergy Information updated/deleted  1  0%
Patient allergic to original med  1  0%
Patient cannot afford original med  1  0%
Nonformulary/insurance issue  0  0%
Total 273 100%
This emphasis was based on both the clinical importance 
to pharmacist as well as the generally low prevalence of 
allergy information available from admission information 
sources – nursing forms, physician orders, and even ambula-
tory data. Although the pharmacist had access to a primary 
care electronic health record (EHR), these records often 
lacked information on allergic reactions. This may have been 
because of simple oversight or because the medications pre-
scribed in the hospital setting are rarely prescribed by primary 
care physicians and the allergies may not be documented in 
the ambulatory chart. Problems with allergy information have 
been reported elsewhere in the literature and some have sug-
gested that pharmacists by given the primary role in allergy 
identiﬁ  cation (Geibig et al 1991; Shenﬁ  eld et al 2001).
Two additional areas suggest themselves for reﬁ  nement 
in this service. First, less than 5% of all recommendations 
at any point in the stay involved deleting a medication. 
Study patients averaged just over 11 medications (includ-
ing over-the-counter and nutritional medications) due to the 
prevalence of chronic disease. However, polypharmacy is 
an important problem in the elderly, and earlier studies have 
demonstrated that more medications increase the risk for 
ADEs (Gandhi et al 2003). A pharmacist checking lab data 
and assessing patient symptoms on a daily basis provides 
a great opportunity to reduce unnecessary medications, 
thereby reducing the chance for medication errors, potential 
side effects, and complex medication regimens that lead to 
poor patient adherence. Pharmacists have been shown to be 
effective in this type of role (Phillips and Carr-Lopez 1990). 
and it is not clear why more medication deletions were not 
recommended within the present study.
Second, there were also few route changes, an area that 
others have found to represent both cost savings and quality 
improvement (Bunz et al 1990; Przybylski et al 1997; Gold-
water et al 1997). In this case, it is likely that few recom-
mendations of this nature were needed, because protocols for 
changing intravenous to oral routes have already been well 
established within this institution.
The long-term impact of clinical pharmacy transitional 
care services in the hospital deserves further study. The 
majority of interventions in this study were done for long-
term beneﬁ  t to the patient, rather than short-term symptom 
relief or safety concern. These beneﬁ  ts would not be captured 
in a cost-beneﬁ  t study that was limited to the duration of the 
hospital stay. Rather, a long-term study would be needed that 
addresses the continuity of adherence with chronic disease 
medications in this population, as well as the impact of this 
continuity on further hospital utilization, morbidity, and 
mortality.
The current study had several limitations, including the 
fact that a single pharmacist collected the data and rated the 
interventions as to type and impact. Although this increased Therapeutics and Clinical Risk Management 2007:3(4) 703
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the consistency of data collection, other coders might have 
interpreted the interventions differently. The four broad 
categories used to estimate impact could benefit from 
further reﬁ  nement. Also, the pharmacist’s estimate of the 
impact of the intervention assumed that others would not 
detect a potential ADE, an assumption that is not always 
true. A dispensing pharmacist through automated or manual 
error checking routines might have caught some errors and 
prevented harm to the patient at a later step in the process. 
Time estimates were approximate and not corroborated via 
intensive time study. It is likely that certain care coordina-
tion tasks and consultations with other staff make up some 
of the time allocated to the time categories used by the TCP 
to estimate her work.
Finally, this study focused on the elderly population, and 
rates of intervention would likely vary for other inpatient 
sub-populations at greater risk (eg, HIV) or lower risk (eg, 
healthy obstetrical patients). While stratiﬁ  ed analyses will 
provide a more in-depth understanding, results from this 
study document the need for targeted, in-depth medication 
reconciliation efforts. Such an approach would beneﬁ  t from 
a controlled trial, with comparison to usual care, and an 
economic evaluation that considers both the costs and the 
areas of cost savings.
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